BioArctic Logo

BioArctic

Develops treatments and diagnostics for neurodegenerative disorders like Alzheimer's and Parkinson's.

BIOA | ST

Overview

Corporate Details

ISIN(s):
SE0010323303 (+1 more)
LEI:
549300Y0OI2WVUNHLC33
Country:
Sweden
Address:
Warfvinges väg 35, 112 51 Stockholm
Sector:
Manufacturing
Industry:
Manufacture of pharmaceuticals, medicinal chemical and botanical products

Description

BioArctic is a Swedish research-intensive biopharmaceutical company focused on developing novel, disease-modifying treatments and diagnostics for neurodegenerative disorders. The company's core mission is to address the underlying causes of diseases such as Alzheimer's and Parkinson's. Its research is centered on developing innovative drugs and antibodies that target the root mechanisms of nerve cell damage and misfolded proteins, aiming to provide effective solutions for significant unmet medical needs within the central nervous system.

Social Media

Unlock This Filing & Millions More

You're one step away from the data you need. Create a free account to instantly view this filing and get access to powerful research tools.

Filings

You have of free filing views remaining. Upgrade for unlimited access.
Quick Filters:

Filters

Clear
Bulk Actions:
Date Filing Language Size Actions
2025-11-13 08:00
Quarterly Report
Swedish 1.8 MB
2025-11-13 08:00
Quarterly Report
English 1.7 MB
2025-10-30 11:00
Earnings Release
Försäljningen av Leqembi® uppgick till 18 miljarder yen under det tredje kvarta…
Swedish 216.8 KB
2025-10-30 11:00
Earnings Release
Sales of Leqembi® totaled 18 billion yen in the third quarter 2025
English 198.1 KB
2025-10-17 15:00
Board/Management Information
BioArctic presents Nomination Committee
English 226.6 KB
2025-10-17 15:00
Board/Management Information
BioArctic presenterar valberedningen
Swedish 225.6 KB
2025-09-29 08:15
Regulatory News Service
Kina godkänner intravenös underhållsbehandling med Leqembi®
Swedish 235.6 KB
2025-09-29 08:15
Regulatory News Service
Leqembi® approved for IV maintenance treatment in China
English 229.9 KB
2025-09-24 08:40
Regulatory News Service
Leqembi® approved for the treatment of early Alzheimer’s disease in Australia
English 237.4 KB
2025-09-24 08:40
Regulatory News Service
Australien godkänner Leqembi® för behandling av tidig Alzheimers sjukdom
Swedish 225.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctics grundare har för avsikt att sälja en mindre del av sitt aktieinnehav
Swedish 182.9 KB
2025-09-03 17:35
Major Shareholding Notification
BioArctic’s founders intend to divest minor part of their shareholding
English 179.0 KB
2025-09-03 01:30
Regulatory News Service
Rolling sBLA initiated to the U.S. FDA for Leqembi® Iqlik™ (lecanemab-irmb) as …
English 211.3 KB
2025-09-03 01:30
Regulatory News Service
Stegvis ansökningsprocess påbörjad för marknadsgodkännande i USA av Leqembi® Iq…
Swedish 253.3 KB
2025-09-01 18:30
Declaration of Voting Results & Voting Rights Announcements
Number of shares and votes in BioArctic AB (publ) as of August 29, 2025
English 196.1 KB

Automate Your Workflow. Get a real-time feed of all BioArctic filings delivered via API.

Explore Data Feeds →

Market Data

Market Data Not Available

Financials & KPIs

No data available

Unlock Full Financials for BioArctic

This data is available as part of our premium data solutions. Contact our team for access.

Need More History? Access decades of standardized financials for BioArctic via our API.

Get Historical Data →

Insider Transactions

Date Insider Name Position Type Shares Value
2025-02-13 Gunilla Osswald Other Sell 40,000 8,821,200.00 SEK
2025-02-13 Gunilla Osswald Other Other 40,000 3,344,000.00 SEK
2025-02-13 Sten Mikael Moge Other Sell 6,000 1,323,180.00 SEK
2025-02-13 Sten Mikael Moge Other Other 6,000 501,600.00 SEK
2025-02-13 Johanna Margareta Fälting Other Sell 1,500 330,795.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 2,500 209,000.00 SEK
2025-02-13 Johanna Margareta Fälting Other Other 1,500 125,400.00 SEK
2025-01-10 Mikael Smedeby Other Buy 730 148,920.00 SEK
2024-12-19 Oskar Bosson Other Sell 2,000 446,000.00 SEK
2024-12-19 Oskar Bosson Other Sell 871 195,626.60 SEK

Peer Companies

2cureX AB Logo
Predicts cancer drug response using 3D tumoroid tests to guide personalized oncology.
Sweden
2CUREX
4BASEBIO PLC Logo
Manufactures GMP-compliant synthetic DNA for advanced therapies, vaccines, and cell/gene therapies.
United Kingdom
4BB
4SC AG Logo
Developing small-molecule epigenetic drugs for high-need cancer indications.
Germany
VSC
60 DEGREES PHARMACEUTICALS, INC. Logo
Develops medicines for tropical diseases, including ARAKODA for malaria prevention.
United States of America
SXTP
89bio, Inc. Logo
Developing therapies for liver and cardiometabolic diseases like MASH and SHTG.
United States of America
ETNB
Aardvark Therapeutics, Inc. Logo
Developing oral drugs to suppress appetite for obesity and rare metabolic diseases.
United States of America
AARD
AbbVie Inc. Logo
A research-based biopharma firm creating medicines for immunology, oncology, and neuroscience.
United States of America
ABBV
ABEONA THERAPEUTICS INC. Logo
Developing AAV-based cell and gene therapies for serious and rare diseases.
United States of America
ABEO
Abera Bioscience AB Logo
Develops next-gen mucosal vaccines using its OMV platform, with a lead pneumococcal candidate.
Sweden
ABERA
ABINGDON HEALTH PLC Logo
A CDMO for lateral flow rapid tests, providing end-to-end services and its own branded products.
United Kingdom
ABDX

Talk to a Data Expert

Have a question? We'll get back to you promptly.